Article

A Comparison of Estrogen Receptor SP1 and 1D5 Monoclonal Antibodies in Routine Clinical Use Reveals Similar Staining Results

Harvard University, Cambridge, Massachusetts, United States
American Journal of Clinical Pathology (Impact Factor: 3.01). 09/2009; 132(3):396-401. DOI: 10.1309/AJCPSKFWOLPPMEU9
Source: PubMed

ABSTRACT Clinical therapies for breast cancer are guided by estrogen receptor (ER) status determined by immunohistochemical analysis. A previous retrospective study comparing the recently generated rabbit SP1 monoclonal antibody (MAb) with the conventionally used mouse 1D5 MAb reported that 8% of breast carcinomas were SP1+/1D5- (correlating with good outcomes), and 2% were SP1-/1D5+ (correlating with poorer outcomes). This study on mostly previously frozen tissue implied that 1D5 fails to identify some women who may benefit from endocrine therapy. The current prospective study compared SP1 and 1D5 immunostaining on routinely processed consecutive cases of breast carcinoma. ER was classified using the same positive threshold used in the prior study (<1% negative; > or = 1% positive). Of 508 carcinomas, 2 were SP1+/1D5-, and none were SP1-/1D5+. Although SP1 is our preferred antibody, with more intense nuclear staining, both MAbs give similar results in tissue from routine clinical samples with discrepant results in fewer than 0.5% of cases.

0 Followers
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Endocrine therapy reduces recurrence risk by 30% to 50% in estrogen receptor (ER)-positive breast cancer. The ER-positive threshold recommended by the American Society of Clinical Oncology/College of American Pathologists is 1% based on studies using the ER-6F11 antibody. ER-SP1 antibody has a higher sensitivity and is more widely used. Methods: We report interobserver concordance manually measuring ER in 264 breast cancers using ER-SP1 and 1D5 and 2 scoring methods (H-score and Allred score). Results: With both antibodies, 3% to 4% of cases have a low level of ER expression (1%-10%), more than previously reported (<1%). We find a high level of paired observer concordance with both antibodies and scoring methods (κ = 0.892-0.943) with no significant difference with method of scoring. Despite excellent concordance, positive/negative discordance was almost 5% among 3 observers using either antibody, an underappreciated clinically significant rate. Conclusions: Discordance overwhelmingly reflected differing opinions recording the proportion of tumor cells positive with low levels of expression (<10% staining; 12/13 cases).
    American Journal of Clinical Pathology 10/2013; 140(4):487-94. DOI:10.1309/AJCP1RF9FUIZRDPI · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context.-Despite advances in breast cancer management, women continue to relapse and die of breast cancer. Traditionally, evaluation for hormone receptors (estrogen and progesterone), as well as HER2 overexpression, have guided therapy-related decision-making because they are both prognostic and predictive indicators. However, there are limitations with those studies, which can lead to improper treatment. Gene signatures have recently been shown to be of value in identifying molecular portraits of breast carcinoma and are beginning to play role in management and treatment algorithms. Objective.-To provide a summary of the prognostic and predictive indicators of breast cancer, such as hormone receptors, HER2, and molecular gene signatures that currently help guide clinical decision making. Data Sources.-Published articles from peer-reviewed journals in PubMed (US National Library of Medicine). Conclusions.-Emerging evidence shows promise that, in addition to hormone receptors and HER2 studies, evaluating tumors with gene expression profiling can provide additional prognostic and predictive information, further aiding clinical management and leading to a more personalized approach to treating breast cancer.
    Archives of pathology & laboratory medicine 01/2014; 138(1):44-56. DOI:10.5858/arpa.2012-0442-RA · 2.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To focus on and compare the tumor hormone receptor profiles on core needle biopsy (CNB) and subsequent surgical excision specimens in a large clinical series of invasive breast carcinoma patients, with regard to guidelines proposed at the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. A total of 993 consecutive patients who had hormone receptors (HR) assays performed on both CNB and subsequent surgical excision specimens of invasive carcinomas were included (1,110 tumors). Concordant tumor HR profiles between CNB and surgical excision specimens were noted in 1,085 of 1,110 tumors (97.75%). Among 138 tumors considered negative on CNB (both HR assays <1%), 10 cases (7.2%) displayed an HR profile positive on surgical excision specimen. Discrepancies between CNBs and surgical excision specimens are very seldom noted. HR assay evaluation on surgical excision specimens should only be considered in patients when both HR assays are negative on CNBs.
    The Breast Journal 11/2013; 19(6):605-10. DOI:10.1111/tbj.12181 · 1.43 Impact Factor